AU669520B2 - Pyrido(2,3-d)pyrimidine derivatives as phosphodiesterase inhibitors - Google Patents

Pyrido(2,3-d)pyrimidine derivatives as phosphodiesterase inhibitors Download PDF

Info

Publication number
AU669520B2
AU669520B2 AU39186/93A AU3918693A AU669520B2 AU 669520 B2 AU669520 B2 AU 669520B2 AU 39186/93 A AU39186/93 A AU 39186/93A AU 3918693 A AU3918693 A AU 3918693A AU 669520 B2 AU669520 B2 AU 669520B2
Authority
AU
Australia
Prior art keywords
pyrido
formula
dione
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39186/93A
Other languages
English (en)
Other versions
AU3918693A (en
Inventor
Robert Alvarez
Ronnie Lipp Chin
Bruce Henry Devens
Robert Stephen Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of AU3918693A publication Critical patent/AU3918693A/en
Application granted granted Critical
Publication of AU669520B2 publication Critical patent/AU669520B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU39186/93A 1992-03-20 1993-03-18 Pyrido(2,3-d)pyrimidine derivatives as phosphodiesterase inhibitors Ceased AU669520B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US855179 1992-03-20
US07/855,179 US5264437A (en) 1992-03-20 1992-03-20 Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
PCT/US1993/002273 WO1993019068A1 (en) 1992-03-20 1993-03-18 PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

Publications (2)

Publication Number Publication Date
AU3918693A AU3918693A (en) 1993-10-21
AU669520B2 true AU669520B2 (en) 1996-06-13

Family

ID=25320543

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39186/93A Ceased AU669520B2 (en) 1992-03-20 1993-03-18 Pyrido(2,3-d)pyrimidine derivatives as phosphodiesterase inhibitors

Country Status (16)

Country Link
US (1) US5264437A (OSRAM)
EP (2) EP1770093A1 (OSRAM)
JP (1) JP3241384B2 (OSRAM)
KR (1) KR100274104B1 (OSRAM)
CN (1) CN1040327C (OSRAM)
AU (1) AU669520B2 (OSRAM)
CA (1) CA2132297C (OSRAM)
FI (1) FI106960B (OSRAM)
HU (2) HUT67552A (OSRAM)
IL (1) IL105092A (OSRAM)
MX (1) MX9301530A (OSRAM)
NO (1) NO301763B1 (OSRAM)
NZ (1) NZ251525A (OSRAM)
TW (1) TW240226B (OSRAM)
WO (1) WO1993019068A1 (OSRAM)
ZA (1) ZA931945B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
MX9706086A (es) * 1995-02-10 1997-10-31 Schering Ag Preparaciones farmaceuticas para inhibicion de tnf.
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2000119272A (ja) * 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
CN1582277A (zh) 2001-11-01 2005-02-16 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的酰胺衍生物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AU2007297212B8 (en) * 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
TW200835497A (en) * 2007-01-11 2008-09-01 Astrazeneca Ab Chemical compounds 636
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
CN102105448B (zh) 2008-05-27 2013-11-13 阿斯利康(瑞典)有限公司 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
US20240400560A1 (en) * 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
CN113831491B (zh) * 2021-09-30 2023-03-24 南昌大学 一种嘧啶唑共价有机框架的制备方法及吸附应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1452877A (en) * 1974-07-05 1976-10-20 Hisamitsu Pharmaceutical Co 2-oxo-1,2,3,4-tetra-hydropyrido-2,3,d-pyrimidines
AU4220193A (en) * 1992-04-29 1993-11-29 Sri International Deazaaminopterins for treatment of inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649917B2 (OSRAM) * 1973-12-18 1981-11-25
DE2523730A1 (de) * 1974-06-12 1976-02-12 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidinonen
EP0260817B1 (en) * 1986-08-21 1991-05-15 Pfizer Inc. Quinazolinediones and pyridopyrimidinediones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1452877A (en) * 1974-07-05 1976-10-20 Hisamitsu Pharmaceutical Co 2-oxo-1,2,3,4-tetra-hydropyrido-2,3,d-pyrimidines
AU4220193A (en) * 1992-04-29 1993-11-29 Sri International Deazaaminopterins for treatment of inflammation

Also Published As

Publication number Publication date
KR100274104B1 (ko) 2000-12-15
TW240226B (OSRAM) 1995-02-11
NO943456D0 (no) 1994-09-16
IL105092A0 (en) 1993-07-08
IL105092A (en) 1998-06-15
US5264437A (en) 1993-11-23
NZ251525A (en) 1996-09-25
HU210873A9 (en) 1995-08-28
EP1770093A1 (en) 2007-04-04
HU9402653D0 (en) 1994-11-28
ZA931945B (en) 1994-09-18
HUT67552A (en) 1995-04-28
CN1040327C (zh) 1998-10-21
CA2132297C (en) 2006-01-03
JP3241384B2 (ja) 2001-12-25
KR950700909A (ko) 1995-02-20
FI944305L (fi) 1994-09-16
CN1078470A (zh) 1993-11-17
FI944305A0 (fi) 1994-09-16
NO301763B1 (no) 1997-12-08
EP0631580A1 (en) 1995-01-04
AU3918693A (en) 1993-10-21
JPH07504676A (ja) 1995-05-25
CA2132297A1 (en) 1993-09-30
WO1993019068A1 (en) 1993-09-30
FI106960B (fi) 2001-05-15
NO943456L (no) 1994-09-16
MX9301530A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
KR100274104B1 (ko) 포스포디에스테라제 억제제로서의 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
AU670544B2 (en) Benzo and pyrido pyridazinone and pyridazinthione compounds with PDE IV inhibiting activity
US5455252A (en) Optionally substituted 6,8-quinolines
US5466697A (en) 8-phenyl-1,6-naphthyridin-5-ones
TWI329644B (en) Novel pyrrole derivatives as pharmaceutical agents
TWI469977B (zh) ７－苯氧基唍羧酸衍生物
KR100256707B1 (ko) 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
CN102131800A (zh) 5元和6元杂环化合物
RU2190612C2 (ru) Новые производные индол-2,3-дион-3-оксима
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
EP0586560A1 (en) Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
US20250179017A1 (en) Carboxamide compounds as pge2 receptor antagonists
US5716954A (en) Benzopyridazinone and pyridopyridazinone compounds
US20040192692A1 (en) 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression
KR101064227B1 (ko) 피라졸로나프티리딘 유도체
KR900004831B1 (ko) 폴리시클릭퀴놀린, 나프티리딘 및 피라지노피리딘 유도체
US5530005A (en) Method of use of 8-phenylcyclopentenoquinoline and 8-phenylcyclohexenoquinoline derivatives
KR20160068948A (ko) RORyt의 이차 알코올 퀴놀리닐 조절제
JPS62223150A (ja) １，４−ベンゾキノン誘導体
WO1993024487A1 (en) Nitrogen containing heterocyclic compounds as angiotensin-ii-antagonists
MXPA98004050A (en) Derivatives of pirido (2,3-d) pyrimidine and pharmaceutical compositions of mis